You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Vedolizumab therapy outcomes and clinical characteristics (n = 28)

From: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Characteristic Clinical remission, No. (%) Clinical failure, No. (%)
Total no. of patients 24 4
Checkpoint inhibitor type
 CTLA-4 6 (25) 2 (50)
 PD-1/L1 11 (46) 1 (25)
 Combination 7 (29) 1 (25)
Mean duration of steroid therapy, days(SD) 95 (79) 99 (52)
Median time from symptom onset to vedolizumab/infliximab therapy, days (IQR) 19 (6–152) 9 (4–67)
Median no. of vedolizumab doses (IQR) 3 (1–4) 3 (1–4)
Mean fecal calprotectin level at time of onset μg/g (SD) 299 (236) 586 (584)
Peak grade of diarrhea
 2 12 (50) 2 (50)
 3–4 12 (50) 2 (50)
Initial endoscopic findings
 Ulceration 6 (25) 3 (75)
 Nonulcerative inflammation 12 (50) 0 (0)
 Normal 6 (25) 1 (25)
Initial histologic findings
 Active features 24 (100) 4 (100)
 Chronic features 10 (42) 4 (100)
 Microscopic 9 (38) 1 (25)
Mean overall duration of disease months (SD) 5 (3) 8 (5)
Mean fecal calprotectin level after vedolizumab therapy μg/g (SD) 187 (108) 270 (487)
Last repeat endoscopic findingsa
 Ulceration 1 (8) 3 (75)
 Nonulcerative inflammation 6 (46) 0 (0)
 Normal 6 (46) 1 (25)
Active features on last repeat histologic analysisa 9 (69) 4 (100)
  1. Abbreviations: SD, standard deviation; IQR, interquartile range
  2. aRepeat endoscopy and histologic analysis was performed in 13 patients with clinical remission